NO173725B - APPLICATION OF A KNOWN MIXTURE TO MANUFACTURE OF AN AGENT FOR HAIR WASTE - Google Patents
APPLICATION OF A KNOWN MIXTURE TO MANUFACTURE OF AN AGENT FOR HAIR WASTE Download PDFInfo
- Publication number
- NO173725B NO173725B NO89890188A NO890188A NO173725B NO 173725 B NO173725 B NO 173725B NO 89890188 A NO89890188 A NO 89890188A NO 890188 A NO890188 A NO 890188A NO 173725 B NO173725 B NO 173725B
- Authority
- NO
- Norway
- Prior art keywords
- hair
- nicotinic acid
- mixture
- stated
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000002699 waste material Substances 0.000 title 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 10
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical group N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 18
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 17
- 229960003512 nicotinic acid Drugs 0.000 claims description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims description 11
- 239000011664 nicotinic acid Substances 0.000 claims description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical group C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229950004580 benzyl nicotinate Drugs 0.000 claims description 4
- -1 nicotinic acid ester Chemical class 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000003656 anti-hair-loss Effects 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 abstract description 20
- 238000002360 preparation method Methods 0.000 abstract description 3
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000004209 hair Anatomy 0.000 description 19
- 208000024963 hair loss Diseases 0.000 description 17
- 230000003676 hair loss Effects 0.000 description 17
- 210000004761 scalp Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 208000001840 Dandruff Diseases 0.000 description 6
- 230000031774 hair cycle Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 206010039792 Seborrhoea Diseases 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004130 lipolysis Effects 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036758 dandruff formation Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000003803 hair density Effects 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- NAIOMPPNMSYCBH-UHFFFAOYSA-N C(C1=CC=CC=C1)C1=C(C(=O)O)C=CC=N1.C(C1=CN=CC=C1)(=O)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)C1=C(C(=O)O)C=CC=N1.C(C1=CN=CC=C1)(=O)OCC1=CC=CC=C1 NAIOMPPNMSYCBH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Oppfinnelsen angår anvendelse av en blanding på basis av en synergistisk og i delområder også antagonistisk virkende kombinasjon ved fremstilling av et middel mot håravfall. The invention relates to the use of a mixture on the basis of a synergistic and in partial areas also antagonistically acting combination in the preparation of an agent against hair loss.
En lokal behandling av det aldersbetingede håravfall hos menn og kvinner med det formål å opprettholde hårgarden (Terminal-haar) er teoretisk mulig etter flere virkningsprinsipper og blir i praksis utført med et resultat som er mer eller mindre godt, men for det meste utilfredsstillende. A local treatment of age-related hair loss in men and women with the aim of maintaining the hair guard (Terminal hair) is theoretically possible according to several principles of action and is carried out in practice with a result that is more or less good, but mostly unsatisfactory.
Til grunn for det aldersbetingede håravfall hos menn ligger et arveanlegg for å reagere på mannlige kjønnshormoner med en akselerert hårcyklus. Det aldersbetingede håravfall hos kvinner beror likeledes på en forsterket androgen stimulering av hårfollikkelen som spesielt etter klimakteriet opptrer i sterkere grad som følge av reduksjon av østrogennivået. At the root of the age-related hair loss in men is a genetic predisposition to react to male sex hormones with an accelerated hair cycle. Age-related hair loss in women is also due to increased androgenic stimulation of the hair follicle, which occurs to a greater extent especially after menopause as a result of a reduction in estrogen levels.
I henhold til Stuttgen og Schåfer (Årztl. Kosmetologie 7, 131-133, 1977) foreligger der en mulighet til opprettholdelse av håret ved aldersbetinget håravfall ved påvirkning av tidsforløpet av den fysiologiske hårcyklus ved målrettet påvirkning av det intracellulære "second messenger" cAMP-system som dannes fra ATP ved hjelp av enzymet adenylcyklase og igjen inaktiveres under innflytelse av en fosfodiesterase. Ved hjelp av disse to enzymer finner reguleringen av det intracellulære cAMP-nivå sted som angitt i skjemaet på neste side. According to Stuttgen and Schåfer (Årztl. Kosmetologie 7, 131-133, 1977) there is a possibility of maintaining the hair in case of age-related hair loss by influencing the time course of the physiological hair cycle by targeted influence of the intracellular "second messenger" cAMP system which is formed from ATP with the help of the enzyme adenyl cyclase and again inactivated under the influence of a phosphodiesterase. With the help of these two enzymes, the regulation of the intracellular cAMP level takes place as indicated in the diagram on the next page.
Under innflytelse av androgener resp. den aktive metabolitt 5-a-dihydrotestosteron som dannes fra testosteron ved hjelp av enzymet 5-a-reduktase, får man en hemming av aktiviteten av adenylcyklase og dermed en hindring resp. reduksjon av cAMP-dannelsen i hårfollikkelen. Dette fører igjen til en forkortelse av anagenfasen og dermed til en økt celledeling innenfor hårcyklusen. Under the influence of androgens or the active metabolite 5-a-dihydrotestosterone, which is formed from testosterone with the help of the enzyme 5-a-reductase, you get an inhibition of the activity of adenyl cyclase and thus an obstacle resp. reduction of cAMP formation in the hair follicle. This in turn leads to a shortening of the anagen phase and thus to increased cell division within the hair cycle.
Da hvert hår bare kan gjennomløpe et bestemt antall vekst-cykluser før det som følge av utmattelse faller ut av follik- As each hair can only go through a certain number of growth cycles before it falls out of the follicle as a result of exhaustion,
HYPOTETISK REGULERING AV HÅRCYKLUS EN VED HJELP AV cAMP I HENHOLD TIL STUTTGEN OG SCHÅFER HYPOTHETICAL REGULATION OF THE HAIR CYCLE BY cAMP ACCORDING TO STUTTGEN AND SCHÅFER
kelen, medfører en forlengelse av anagenfasen og dermed hele hårcyklusen (redusert celledelingshastighet) ved målrettet påvirkning av cAMP-systemet en mulighet for behandling av det aldersbetingede håravfall i retning av en opprettholdelse av hårbestanden. the keel, an extension of the anagen phase and thus the entire hair cycle (reduced cell division rate) by targeted influence of the cAMP system leads to an opportunity to treat the age-related hair loss in the direction of maintaining the hair population.
En slik påvirkning av cAMP-systemet kan finne sted på forskjel-lige måter: 1. Opphevelse av den hemming av adenylcyklase som bevirkes av 5-a-dihydrotestosteron ved hjelp av antiandrogener såsom cyproteronacetat, 17-a-hydroksyprogesteron, spironolakton eller 17-B-estradiol, nærmere bestemt enten ved direkte hemming av 5-a-reduktasen eller blokkering av 5-a-dihydrotestosteron-spe-sifike reseptorer. 2. En økning i det intracellulære cAMP-nivå kan imidlertid også nås via en hemming av fosfodiesterase ved hjelp av metylxantiner såsom koffein og teofyllin. En slik påvirkning av cAMP-systemet ved hjelp av ikke-hormonelle aktive stoffer hvis giftighet kan bestemmes, er avgjørende å foretrekke som alternativ til den i punkt 1 beskrevne hormonterapi, som spesielt hos menn er beheftet med til dels ikke ubetenkelige bivirkninger. Such an influence on the cAMP system can take place in different ways: 1. Cancellation of the inhibition of adenyl cyclase caused by 5-a-dihydrotestosterone by means of antiandrogens such as cyproterone acetate, 17-a-hydroxyprogesterone, spironolactone or 17-B -estradiol, more precisely either by direct inhibition of the 5-a-reductase or blocking of 5-a-dihydrotestosterone-specific receptors. 2. However, an increase in the intracellular cAMP level can also be achieved via an inhibition of phosphodiesterase by means of methylxanthines such as caffeine and theophylline. Such an influence on the cAMP system by means of non-hormonal active substances, the toxicity of which can be determined, is decisively preferable as an alternative to the hormone therapy described in point 1, which, especially in men, is fraught with partly not inconsiderable side effects.
Virkningen av koffein som det sterkeste hemmende stoff for fosfodiesterase - også på menneskets hodebunn - er kjent fra Arzt. Kosmetologie 14, 209-220 (1984). The effect of caffeine as the strongest inhibitory substance for phosphodiesterase - also on the human scalp - is known from Arzt. Cosmetology 14, 209-220 (1984).
Årztliche Kosmetologie 10, 163-187 (1980) beskriver anvendelsen av en blanding av nikotinsyrebenzylester og koffein i salve-baser til behandling av hudsykdommer. Årztliche Kosmetologie 10, 163-187 (1980) describes the use of a mixture of nicotinic acid benzyl ester and caffeine in ointment bases for the treatment of skin diseases.
Den foreliggende oppfinnelse går ut på anvendelse av en blanding som inneholder 0,1-1,0 vektprosent av et metylxantin og/eller minst ett derivat herav og 0,1-0,25 vektprosent av en nikotinsyreester samt eventuelt buffersubstanser, stabilisatorer og parfymeringsoljer foruten vanlige bærere og/eller fortynningsmidler, ved fremstilling av et middel mot håravfall. The present invention involves the use of a mixture containing 0.1-1.0 weight percent of a methylxanthine and/or at least one derivative thereof and 0.1-0.25 weight percent of a nicotinic acid ester as well as possibly buffer substances, stabilizers and perfume oils in addition usual carriers and/or diluents, in the preparation of an agent against hair loss.
Den blanding som skal anvendes ifølge oppfinnelsen, har en synergistisk og også antagonistisk virkning. Celledelings-hastigheten i hodehåret blir redusert ved en biokjemisk påvirkning av hårcyklusenes tidsforløp. Videre stimuleres blodgjennomstrømningen av hodehuden, og seborré samt flass reduseres. The mixture to be used according to the invention has a synergistic and also antagonistic effect. The rate of cell division in the scalp is reduced by a biochemical effect of the time course of the hair cycle. Furthermore, the blood flow of the scalp is stimulated, and seborrhea and dandruff are reduced.
Som metylxantin anvendes fortrinnsvis teofyllin eller koffein, og koffein (1,3,7-trimetylxantin) er særlig foretrukket. As methylxanthine, theophylline or caffeine are preferably used, and caffeine (1,3,7-trimethylxanthine) is particularly preferred.
Foruten den beskrevne biokjemiske virkning av koffeinet på cAMP-systemet bevirker koffein også en vasodilatasjon, dvs. en utvidelse av blodkarene, spesielt i området for mikrosirkula-sjonen. Som følge av denne fremmende virkning på blodgjen-nomstrømningen får hårfolliklene igjen tilført næringsmidler og oksygen i større grad, noe som spesielt ved aldersbetinget håravfall er av stor betydning som følge av den her forekom-mende for sterke stramning av hodehuden og den hermed ofte forbundne reduserte blodgjennomstrømning. Videre har koffein også en utpreget virkning mot flass. In addition to the described biochemical effect of caffeine on the cAMP system, caffeine also causes vasodilatation, i.e. an expansion of the blood vessels, especially in the area of the microcirculation. As a result of this promoting effect on blood flow, the hair follicles are once again supplied with nutrients and oxygen to a greater extent, which is particularly important in the case of age-related hair loss due to the excessive tightening of the scalp that occurs here and the often associated reduced blood flow. Furthermore, caffeine also has a distinct effect against dandruff.
Som nikotinsyreester foretrekkes nikotinsyrebenzylester (benzylnikotinat) . Nikotinsyrebenzylester er et stoff som likeledes - og faktisk i enda sterkere grad etter lokal påføring - øker blodgjennomstrømningen, spesielt i kapillarområdet, og således i kombinasjon med metylxantin eller et derivat herav oppviser synergistisk virkning. Som følge av sin fettoppløselighet trenger nikotinsyrebenzylesteren raskt inn i hornlaget og blir hydrolysert av esteraser til nikotinsyre inne i de levende hudskikt. Dens intensive fremmende virkning på blodgjennomstrømningen i kapillarområdet fører til en økning av blodmengden i det behandlede område av hodebunnen (rødming) som kan vedvare i flere timer. As nicotinic acid ester, nicotinic acid benzyl ester (benzyl nicotinate) is preferred. Nicotinic acid benzyl ester is a substance which likewise - and in fact to an even stronger degree after local application - increases blood flow, especially in the capillary area, and thus in combination with methylxanthine or a derivative thereof exhibits a synergistic effect. As a result of its fat solubility, the nicotinic acid benzyl ester quickly penetrates the stratum corneum and is hydrolysed by esterases to nicotinic acid inside the living skin layers. Its intensive promoting effect on the blood flow in the capillary area leads to an increase in the amount of blood in the treated area of the scalp (redness) which can persist for several hours.
Som følge av nikotinsyrens store biokjemiske virkningsspektrum som forløper for pyridinnukleotider (koenzymer av dehydroge-nase) påvirker den indirekte en rekke stoffskiftereaksjoner som også vil kunne spille en rolle ved utviklingen av aldersbetinget håravfall. As a result of nicotinic acid's large biochemical spectrum of action as a precursor for pyridine nucleotides (coenzymes of dehydrogenase), it indirectly affects a number of metabolic reactions which could also play a role in the development of age-related hair loss.
Da der ved aldersbetinget håravfall meget ofte foreligger en såkalt "følgeseborré", dvs. en økning av hodebunn- og hår-lipidene, kommer en ytterligere egenskap av nikotinsyren - nærmere bestemt dens lipolysehemmende virkning - til nytte i det beskrevne hår- og hodebunnmiddel: da lipolysen (spalting av triglyceridene i fettsyrer og glycerin) i talgkjertlene og den tilgrensende hodehud forårsakes av mikrober, foreligger der prinsippielt to måter å redusere høye fettsyreandeler på: 1) En hemming av lipolysen ved antimikrobielle stoffer såsom isopropanol, som også kan anvendes som fortynningsmiddel i den blanding som anvendes ifølge oppfinnelsen. 2) En biokjemisk påvirkning av lipolysen som følge av den målrettede hemming av triglyceridlipasen ved hjelp av nikotinsyre: Nikotinsyren er et av de kraftigste hemmende stoffer for diglyceridlipasen. Since with age-related hair loss there is very often a so-called "accompanying dysentery", i.e. an increase in the scalp and hair lipids, a further property of nicotinic acid - specifically its lipolysis-inhibiting effect - comes in handy in the described hair and scalp remedy: lipolysis (splitting of the triglycerides into fatty acids and glycerin) in the sebaceous glands and the adjacent scalp is caused by microbes, there are basically two ways to reduce high fatty acid levels: 1) An inhibition of lipolysis by antimicrobial substances such as isopropanol, which can also be used as a diluent in the mixture used according to the invention. 2) A biochemical effect on lipolysis as a result of the targeted inhibition of triglyceride lipase by means of nicotinic acid: Nicotinic acid is one of the most powerful inhibitory substances for diglyceride lipase.
Det er nå blitt funnet at nikotinsyre på en fremragende måte utøver denne hemmende virkning på triglyceridlipasen også i nærvær av metylxantiner eller derivater herav og et økt cAMP-nivå, da dens angrepspunkt tilsynelatende ligger "lipase-nærmere". Således antagoniserer nikotinsyren i kombinasjon med metylxantinet eller et derivat herav ikke den ønskede økning av cAMP-nivået i hårfollikkelen som er ønsket, men derimot den sekundære aktivering av triglyceridlipasen i talgkjertlen og den dermed istandbragte frigjøring av fettsyrer. It has now been found that nicotinic acid exerts this inhibitory effect on triglyceride lipase in an outstanding manner also in the presence of methylxanthines or derivatives thereof and an increased cAMP level, as its point of attack is apparently "closer to lipase". Thus, the nicotinic acid in combination with the methylxanthine or a derivative thereof does not antagonize the desired increase in the cAMP level in the hair follicle, which is desired, but instead the secondary activation of the triglyceride lipase in the sebaceous gland and the resulting release of fatty acids.
Et symptom som ofte opptrer ved aldersbetinget håravfall foruten selve håravfallet og følgeseborréen, er en økt flassdannelse. Hodeflass utgjør det synlige motstykket til en økt celledelingshastighet i overhuden. Derav følger en "omsetning" av epidermale celler som etter vandring gjennom den levende overhud og hornlaget avstøtes som store cellekomplek-ser. Behandlingen av økt flassdannelse kan finne sted ved en reduksjon av den økte celledelingshastighet og ved anvendelse av stoffer med keratolytisk virkning. A symptom that often occurs with age-related hair loss, apart from the hair loss itself and the accompanying dysentery, is increased dandruff formation. Dandruff is the visible counterpart of an increased rate of cell division in the epidermis. This results in a "turnover" of epidermal cells which, after traveling through the living epidermis and stratum corneum, are rejected as large cell complexes. The treatment of increased dandruff formation can take place by reducing the increased rate of cell division and by using substances with a keratolytic effect.
Salicylsyre er et velkjent middel med keratolytisk virkning. Fortrinnsvis inneholder den ifølge oppfinnelsen anvendte blanding således i tillegg salicylsyre, spesielt i en mengde på 0,5 vektprosent regnet på blandingen. Salicylic acid is a well-known agent with keratolytic action. Preferably, the mixture used according to the invention thus additionally contains salicylic acid, especially in an amount of 0.5% by weight based on the mixture.
Som fortynningsmiddel anvendes fortrinnsvis etanol og/eller isopropanol. Således kan blandingen f.eks. inneholde 30-70% etanol og/eller isopropanol, mens resten av fortynningsmiddelet kan være vann. Ethanol and/or isopropanol are preferably used as diluents. Thus, the mixture can e.g. contain 30-70% ethanol and/or isopropanol, while the rest of the diluent can be water.
Det hår- og hodebunnmiddel som fremstilles ifølge oppfinnelsen, er blitt undersøkt på menn og kvinner med aldersbetinget håravfall : Undersøkelseskriteriene var dels subjektive symptomer såsom smerter og kløe i området for hårbunnen og graden av håravfall, dels objektive symptomer såsom seborré, hodeflass og grad av håruttynning, og videre en kvantitativ bedømmelse av hår-vekstkapasiteten samt bestemmelse av hårtettheten. The hair and scalp agent produced according to the invention has been examined on men and women with age-related hair loss: The examination criteria were partly subjective symptoms such as pain and itching in the area of the scalp and the degree of hair loss, partly objective symptoms such as seborrhea, dandruff and degree of hair thinning , and further a quantitative assessment of the hair growth capacity as well as determination of the hair density.
Materialer oa metoder: Materials and other methods:
Åtte personer deltok i undersøkelsene. Syv var menn i alderen 22-28 år, mens én var en kvinne på 67 år. Behandlingen med hår-middelet strakte seg over 6 måneder. I løpet av dette tidsrom ble der ikke anvendt ytterligere hårmidler, hverken utvortes eller innvortes. Eight people participated in the surveys. Seven were men aged 22-28, while one was a 67-year-old woman. The treatment with the hair remedy stretched over 6 months. During this period, no additional hair products were used, either externally or internally.
Hårvask fant sted med den samme sjampoo så ofte som det var nødvendig etter de kosmetiske behov hos de enkelte personer. Hair washing took place with the same shampoo as often as was necessary according to the cosmetic needs of the individual persons.
Før behandlingen, etter 3 måneders behandling og etter 6 måneders behandling ble for det første subjektive anførsler fra personene med hensyn til smerter og kløing i området for hårbunnen samt med hensyn til intensiteten av håravfallet notert. Dessuten ble objektive symptomer såsom seborré, hodeflass og håruttynning bedømt av den samme undersøkelsesper-son før, under og etter behandlingen. Videre ble hårrotmønste-ret ved forenden av hårvekstområdet og på bakhodet bestemt (trichogrammer) ved begynnelsen av behandlingen og etter 3 måneders og 6 måneders behandling. I tillegg ble antall hår på et sirkelformet areal med en diameter av 2,5 cm i isse/bak-hode-området bestemt. Ved hjelp av en sjablong ble det sikret at tellingen av hårene altid ble utført i det samme område. Before the treatment, after 3 months of treatment and after 6 months of treatment, subjective statements from the subjects with regard to pain and itching in the area of the scalp as well as with regard to the intensity of the hair loss were noted. In addition, objective symptoms such as seborrhea, dandruff and hair thinning were assessed by the same examiner before, during and after the treatment. Furthermore, the hair root pattern at the front end of the hair growth area and on the back of the head was determined (trichograms) at the beginning of the treatment and after 3 months and 6 months of treatment. In addition, the number of hairs on a circular area with a diameter of 2.5 cm in the ise/back of the head area was determined. With the help of a stencil, it was ensured that the counting of the hairs was always carried out in the same area.
Resultater Results
Subjektive symptomer. Alle personer rapporterte en reduksjon av smerter og kløing i området for hårbunnen. Syv personer anførte en bedring mht. intensiteten av håravfallet. Subjective symptoms. All subjects reported a reduction in pain and itching in the scalp area. Seven people stated an improvement regarding the intensity of hair loss.
Objektive symptomer. Hos alle personer kunne der observeres en tydelig reduksjon av en seborré som forelå ved begynnelsen av behandlingen. Videre kunne der observeres en reduksjon av flass som forelå før behandlingen. Med hensyn til stadiuminndelingen av aldersbetinget håravfall i henhold til Hamilton kunne der ikke påvises noen endring i løpet av forsøksperioden. Objective symptoms. In all subjects, a clear reduction of a seborrhea that was present at the beginning of the treatment could be observed. Furthermore, a reduction of dandruff that was present before the treatment could be observed. With regard to the stage division of age-related hair loss according to Hamilton, no change could be detected during the trial period.
Obiektiv- kvantitativ måling av hårveksten. Objective quantitative measurement of hair growth.
Hårrotmønster. Trichogramkontroller ved begynnelsen av behandlingen, etter 3 måneders behandling og etter 6 måneders behandling viste ingen vesentlige endringer hos tre personer. Hos fem personer opptrådte det imidlertid etter 6 måneders behandling en til dels tydelig økning av den prosentuelle andel anagent hår og en reduksjon av den prosentuelle andel telogen-hår. Hair root pattern. Trichogram checks at the beginning of treatment, after 3 months of treatment and after 6 months of treatment showed no significant changes in three people. However, in five people, after 6 months of treatment, there was a partly clear increase in the percentage of anagen hair and a reduction in the percentage of telogen hair.
Hårtetthet. Antall hår på et sirkelformet areal med en diameter på 2,5 cm i isse/bakhode-området viste for alle de avsluttede åtte behandlingstilfeller en økning av antall hår. Hair density. The number of hairs in a circular area with a diameter of 2.5 cm in the forehead/back of the head area showed an increase in the number of hairs in all eight completed treatment cases.
Claims (6)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3801034A DE3801034A1 (en) | 1988-01-15 | 1988-01-15 | HAIR AND SCALP TREATMENT |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO890188D0 NO890188D0 (en) | 1989-01-16 |
| NO890188L NO890188L (en) | 1989-07-17 |
| NO173725B true NO173725B (en) | 1993-10-18 |
| NO173725C NO173725C (en) | 1994-01-26 |
Family
ID=6345358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO890188A NO173725C (en) | 1988-01-15 | 1989-01-16 | The use of a known composition for the preparation of a hair loss agent |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0325969B1 (en) |
| AT (1) | ATE88084T1 (en) |
| DE (2) | DE3801034A1 (en) |
| DK (1) | DK16389A (en) |
| ES (1) | ES2010161A4 (en) |
| NO (1) | NO173725C (en) |
| PT (1) | PT89463B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USH1480H (en) * | 1993-12-09 | 1995-09-05 | The Procter & Gamble Company | Methods of using dyphylline for the promotion of hair growth |
| US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
| FR2751541B1 (en) * | 1996-07-25 | 1998-10-23 | Fabre Pierre Dermo Cosmetique | DERMO-COSMETIC COMPOSITION CONTAINING A QUINQUINA ALKALOID AND METHOD FOR THE COSMETIC TREATMENT OF ALOPECIA |
| BRPI0311568B1 (en) * | 2002-07-05 | 2017-06-20 | Unilever N.V | Use of a topical composition and uses of an α-hydroxy acid |
| DE102005003949A1 (en) * | 2005-01-27 | 2005-08-04 | Alcina Cosmetic Dr. Kurt Wolff Gmbh & Co. Kg | Caffeine-containing agent, useful to activate hair-roots, comprises surfactants as an anionic penetration enhancer |
| DE102006050984A1 (en) * | 2006-10-26 | 2008-04-30 | Henkel Kgaa | Cosmetic agent, useful e.g. as hair treating agent, and to increase the elasticity of keratin fibers, preferably human hairs, comprises purine and/or its derivative, coolness producing substances and/or heatness producing substance |
| DE102007013143A1 (en) * | 2007-03-15 | 2008-10-02 | Henkel Ag & Co. Kgaa | Use of purine and purine derivatives for hair treatment |
| WO2009107073A1 (en) * | 2008-02-29 | 2009-09-03 | The Procter & Gamble Company | Methods, kits and method of marketing for increasing hair diameter and delivering additional benefits |
| CN101959495A (en) * | 2008-02-29 | 2011-01-26 | 宝洁公司 | Hair care compositions and methods for increasing hair diameter |
| WO2009107075A1 (en) * | 2008-02-29 | 2009-09-03 | The Procter & Gamble Company | Hair care compositions and methods for increasing hair diameter and for immediate fuller/thicker hair appearance |
| WO2009107074A1 (en) * | 2008-02-29 | 2009-09-03 | The Procter & Gamble Company | Hair care compositions and methods for increasing hair diameter and delivering additional benefits |
| DE202018101021U1 (en) | 2017-02-24 | 2018-03-07 | Liudmila Kalitukha | Means for normalizing hair growth and head condition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE835038C (en) * | 1951-01-16 | 1952-03-27 | Nordmark Werke Gmbh | Hair care products |
| DE1900726A1 (en) * | 1969-01-08 | 1970-08-13 | Dr Momcilo Veskovic | Hair restorer |
-
1988
- 1988-01-15 DE DE3801034A patent/DE3801034A1/en active Granted
-
1989
- 1989-01-13 EP EP89100600A patent/EP0325969B1/en not_active Expired - Lifetime
- 1989-01-13 DK DK016389A patent/DK16389A/en not_active Application Discontinuation
- 1989-01-13 ES ES89100600T patent/ES2010161A4/en active Pending
- 1989-01-13 AT AT89100600T patent/ATE88084T1/en active
- 1989-01-13 DE DE8989100600T patent/DE58904029D1/en not_active Expired - Fee Related
- 1989-01-16 NO NO890188A patent/NO173725C/en unknown
- 1989-01-16 PT PT89463A patent/PT89463B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3801034C2 (en) | 1990-10-25 |
| NO890188L (en) | 1989-07-17 |
| EP0325969B1 (en) | 1993-04-14 |
| DK16389D0 (en) | 1989-01-13 |
| DE3801034A1 (en) | 1989-07-27 |
| PT89463A (en) | 1990-02-08 |
| PT89463B (en) | 1993-12-31 |
| ES2010161A4 (en) | 1989-11-01 |
| DK16389A (en) | 1989-07-16 |
| DE58904029D1 (en) | 1993-05-19 |
| ATE88084T1 (en) | 1993-04-15 |
| NO173725C (en) | 1994-01-26 |
| EP0325969A1 (en) | 1989-08-02 |
| NO890188D0 (en) | 1989-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5183817A (en) | Combinations of retinoids and minoxidil-type compounds for hair growth | |
| Pandhi et al. | Premature graying of hair | |
| NO173725B (en) | APPLICATION OF A KNOWN MIXTURE TO MANUFACTURE OF AN AGENT FOR HAIR WASTE | |
| JP2000226317A (en) | Hair lotion having improved properties in hair-protecting action, hair reduction-preventing action and action for lowering external action of androgenic alopecia and the resulting hair damage | |
| US8492353B2 (en) | Antiaging composition | |
| JP2018087187A (en) | Composition containing sophorolipid as active ingredient for preventing hair loss or promoting hair growth | |
| Bloch et al. | Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss | |
| EP2512420B1 (en) | Use of 2,3-dihydroxypropyl dodecanoate for treating seborrhea | |
| AU2009203355B2 (en) | Composition for external application | |
| US5116606A (en) | Skin treatment method and solution | |
| KR20190136423A (en) | Composition for enhancing the action for hair growth of adipose stem comprising udenafil as an active ingredient | |
| JP2022024400A (en) | Hair restorer/grower | |
| RU2431485C2 (en) | Method of treating hair growth disorder, such as female pattern of hair loss, and compositions applied therein | |
| US5609858A (en) | Method for treatment of androgenic alopecia | |
| US6531140B2 (en) | Anti-irritant compositions containing a cyclic nucleotide | |
| JPS5857308A (en) | Agent for growing and nourishing hair | |
| CN101170992A (en) | Composition comprising wortmannin and its topical use for reducing human hair growth | |
| John et al. | Emerging oral treatments: oral minoxidil for androgenetic alopecia | |
| JP2013540135A (en) | Hair growth promoter | |
| Khalid | Medical Treatment of Alopecia | |
| DE2757024A1 (en) | Hair and skin cosmetics - contg. 11-alpha-hydroxy-progesterone | |
| CA1238281A (en) | Hair treating agent and method of treating hair | |
| Gan et al. | Androgenetic alopecia | |
| UA140524U (en) | ADENOSINE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALOPECIA | |
| JPS6118711A (en) | Hair tonic |